[1] | De Ritis G., Auricchio S, Jones H W, Lew E J L, Bernardin J E & Kasarda D. (1988) In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in coeliac disease. Gastroenterology. 94: 41-49. |
|
[2] | Gottlieb K, Donovan J, Hussain F and Murray J A. (2015) Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials. Gastroenterology Report, 1-12 Oxford. |
|
[3] | Wungiranirun M, Kelly C.P. and Leffler D A. (2016) Current status of celiac disease drug development. J Gastroenterology. |
|
[4] | Ludvigsson J F, Rubio-Tapia A, van Dyke CT, et al. (2013) Increasing incidence of celiac disease in a North American population. Am J Gastroenterol. 108: 818-824. |
|
[5] | Lohi S, Mustalahti K, Kaukinen K, et al. (2007) Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 26: 1217-25. |
|
[6] | Rubio-Tapia A, Hill ID, Kelly CP, et al. (2013) ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 108: 656-76. |
|
[7] | West J, Logan R F, Smith C J et al. (2004) Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ. 329: 716-719. |
|
[8] | Hall NJ, Rubin GP, Charnock A. (2013) Intentional and inadvertent non-adherence in adult coeliac disease. A cross-sectional survey. Appetite 68: 56-62. |
|
[9] | Cornell H J, Macrae F A, Melny J, Pizzey C, Cook F, Mason S, Bhathal P & Stelmasiak T. (2005) Enzyme therapy for management of coeliac disease. Scand. J. Gastroent. 40: 1304-1312. |
|
[10] | Zebrowska A, Cornell HJ, Macrae FA, Sysa-Jedrzejowska A, Waszczykowska A, Stelmasiak T. (2014) The effect of enzyme therapy on skin symptoms and immune responses in patients with dermatitis herpetiformis. International Journal of Celiac Disease. 2 (2): 58-63. |
|
[11] | Cornell H J, Czyzewska A , Macrae F A, Rydzewska G, Nasierowska-Gutmejer A, Bednarczuk A and Stelmasiak T (2016) The Effect of Enzyme Supplementation on Symptoms and Duodenal Histology in Celiac Patients. International Journal of Celiac Disease. 4, No. 2, xx. |
|
[12] | Kocna P, Mothes T, Krchnak V & Fric P (1991). Relationship between gliadin peptide structure and their effect on the foetal chick duodenum. Z. Lebensm. Unters. Forsch. 192: 116-119. |
|
[13] | Cornell HJ, & Rivett DE (1995). In vitro mucosal digestion of synthetic gliadin-derived peptides in coeliac disease. J Protein Chem. 14: 335-339. |
|
[14] | Mothes T, Muhle W, Muller F & Herkens WTJM (1985). Influence of gliadin on foetal chick intestine in tissue culture. Biol Neonate. 48: 59-64. |
|
[15] | Cornell HJ, Mothes T (1993). The activity of wheat gliadin peptides in in vitro assays for coeliac disease. Biochim Biophys Acta. 1181: 169-173. |
|
[16] | Cornell HJ, Mothes T (1995). Further studies of the in vitro activity of synthetic gliadin peptides in coeliac disease. Biochim Biophys Acta. 1270: 168-172. |
|
[17] | Cornell HJ, Wieser H. & Belitz, HD (1992). Characterisation of the gliadin-derived peptides which are biologically active in coeliac disease. Clin Chim Acta. 213: 37-50. |
|
[18] | Mantzaris, GJ, & Jewell DP (1991). In-vivo toxicity of a synthetic dodecapeptide from A-gliadin in patients with coeliac disease. Scand J Gastroenterol. 26: 392-398. |
|
[19] | Giovannini C, Luchetti R and De Vincenzi M (1997) The activities of peptides “31-43” and “56-68” of A-gliadin on in vitro cultures of Ca Co-2 cells. ATLA 25:437-443. |
|
[20] | Shan L., Molberg Ø, Parrot I., Hausch F, Filiz F, Gray GM, Sollid LM & Khosla C. (2002.) Structural basis for gluten intolerance in coeliac sprue. Science. 297: 2275-2279. |
|
[21] | Anderson RP, Degano P, Godkin A J, Jewell D P & Hill A V S. (2000) In vivo antigen challenge in celiac disease identifies a single traqnsglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nature Medicine. 6 (3): 337-342. |
|
[22] | Cornell H.J., Skerritt J.H., Puy R.& Javadpour M. (1994). Studies of in vitro γ- interferon production in coeliac disease as a response to gliadin peptides. Biochim Biophys Acta. 1226: 126-130. |
|
[23] | Cornell H.J. &Wills-Johnson G. (2001). Structure-activityrelationships in coeliac-toxic gliadin peptides. Amino Acids. 21: 243-253. |
|
[24] | Sturgess, R., Day P., Ellis H.J., Lundin K.E., Gjertsen,H.A., Kontakou M. & Ciclitir, P.J. (1994).Wheat peptide challenge in coeliac disease. Lancet. 343: 758-761. |
|
[25] | McLachlan A., Cullis, P.G., Cornell, H.J. (2002). The use of extended motifs for focussing on toxic peptides in coeliac disease. J. Biochem. Mol. Biol. Biophys. 6: 319-324. |
|
[26] | Cornell H.J. (1998). Partial in vitro digestion of active gliadin-related peptides in coeliac disease. J Protein Chem. 17: 739-744. |
|
[27] | Cornell H.J. & Townley R.R.W. (1973). Investigating possible intestinal peptidase deficiency in coeliac disease. Clin Chim Acta..43: 113-125. |
|
[28] | Cornell H.J., Doherty W. & Stelmasiak T. (2010). Papaya enzymes capable of detoxification of gliadin. Amino Acids. 38: 165-175. |
|
[29] | Stepniak D, Spaenij-Dekking L, Mitea C, Moester M, de Ru A, Baak-Pablo R, van Veelen P, Edens L & Konig F. (2006). Highly efficient gluten degradation with newly identified prolyl endopeptidase: implications for celiac disease. Am. J, Physiol. Gastrointest. Liver Physiol. 291: G621-629. |
|
[30] | Cornell H.J. & Stelmasiak T. (2011) Caricain - a basis for enzyme therapy for coeliac disease. Sth Afr J Sci..9/10: 107-111. |
|
[31] | Zerhovni S, Amrani M, Nijs M, Smolders N, Azarkan M, Vincentelli J & Loose Y. (1998) Purification and characterisation of papaya cyclotransferase, a plant enzyme highly resistant to chemical, acid and thermal denaturation. Biochimica et Biophysica Acta. 1387: 275-290. |
|
[32] | Janssen G, Christis C, Kooy-Winkelaar Y, Edens L, Smith D and van Veelen P. (2015) Ineffective degradation of immunogenic gluten epitops by currently available digestive enzyme supplements. PLOS ONE. |
|
[33] | Uhde M, Ajamian M, Caio G, De Giorgio R, Indart A, Green P, Verna E C, Volta U, Alaedini A. Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease Gut. |
|
[34] | Graf L, Horvath K, Walez E, Beazetei I and Burnier J. (1987) Effect of two synthetic α-gliadin peptides on lymphocytes in celiac disease: identification of a novel class of opioid receptors. Neuropeptides. 9:113-122. |
|